Wells Fargo & Company Pasithea Therapeutics Corp. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.28 - $0.48 $6 - $11	-24 Reduced 15.89%	127 $0
Q3 2023 Nov 13, 2023	BUY	$0.44 - $0.63 $14 - $20	32 Added 26.89%	151 $0
Q2 2023 Aug 15, 2023	SELL	$0.31 - $0.5 $2 - $4	-8 Reduced 6.3%	119 $0
Q1 2023 May 12, 2023	BUY	$0.38 - $0.73 $4 - $8	12 Added 10.43%	127 $0
Q4 2022 Feb 13, 2023	BUY	$0.55 - $26.0 $2 - $104	4 Added 3.6%	115 $0
Q3 2022 Nov 14, 2022	BUY	$0.08 - $26.4 $1 - $422	16 Added 16.84%	111 $0
Q2 2022 Aug 12, 2022	BUY	$16.52 - $27.0 $181 - $297	11 Added 13.1%	95 $0
Q1 2022 May 16, 2022	BUY	$19.4 - $35.8 $1,047 - $1,933	54 Added 180.0%	84 $0
Q4 2021 Feb 14, 2022	BUY	$28.8 - $112.0 $864 - $3,360	30 New	30 $0

Ticker KTTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,398,700
Market Cap $157M
Description
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.